In a validation study involving 156 patients with metastatic CRC, LMCC patients with RAS wild-type tumors exhibited significantly higher response rates to anti-EGFR antibody therapy (33.3% vs. 4.2%, p = 0.004), longer PFS (6.6 vs. 2.5 months, HR = 0.22, p < 0.001), and improved OS (15.5 vs. 5.6 months, HR = 0.23, p < 0.001) compared to HMCC patients [82]. The gene discussed is EGFR; the disease is colorectal carcinoma.